0001714899-21-000117.txt : 20211230
0001714899-21-000117.hdr.sgml : 20211230
20211230215944
ACCESSION NUMBER: 0001714899-21-000117
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211228
FILED AS OF DATE: 20211230
DATE AS OF CHANGE: 20211230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessier-Lavigne Marc
CENTRAL INDEX KEY: 0001437435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38311
FILM NUMBER: 211534381
MAIL ADDRESS:
STREET 1: 1 DNA WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Denali Therapeutics Inc.
CENTRAL INDEX KEY: 0001714899
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 463872213
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 866-8548
MAIL ADDRESS:
STREET 1: 161 OYSTER POINT BLVD.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
wf-form4_164091956763788.xml
FORM 4
X0306
4
2021-12-28
0
0001714899
Denali Therapeutics Inc.
DNLI
0001437435
Tessier-Lavigne Marc
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
1
0
0
0
Common Stock
2021-10-04
5
G
0
E
300000
0
D
2244370
D
Common Stock
2021-10-04
5
G
0
E
100000
0
A
100000
I
The Tessier-Lavigne/Hynes Irrevocable Trust 1
Common Stock
2021-12-28
4
S
0
3732
44.37
D
96268
I
The Tessier-Lavigne/Hynes Irrevocable Trust 1
Common Stock
2021-12-29
4
S
0
10700
43.88
D
85568
I
The Tessier-Lavigne/Hynes Irrevocable Trust 1
Common Stock
2021-12-30
4
S
0
3343
45.13
D
82225
I
The Tessier-Lavigne/Hynes Irrevocable Trust 1
Common Stock
2021-12-30
4
S
0
3377
45.59
D
78848
I
The Tessier-Lavigne/Hynes Irrevocable Trust 1
Common Stock
2021-10-04
5
G
0
E
100000
0
A
100000
I
The Tessier-Lavigne/Hynes Irrevocable Trust 2
Common Stock
2021-12-28
4
S
0
3602
44.38
D
96398
I
The Tessier-Lavigne/Hynes Irrevocable Trust 2
Common Stock
2021-12-29
4
S
0
10700
43.87
D
85698
I
The Tessier-Lavigne/Hynes Irrevocable Trust 2
Common Stock
2021-12-30
4
S
0
5625
45.31
D
80073
I
The Tessier-Lavigne/Hynes Irrevocable Trust 2
Common Stock
2021-12-30
4
S
0
900
45.71
D
79173
I
The Tessier-Lavigne/Hynes Irrevocable Trust 2
Common Stock
2021-10-04
5
G
0
E
100000
0
A
100000
I
The Tessier-Lavigne/Hynes Irrevocable Trust 3
Common Stock
2021-12-28
4
S
0
3646
44.37
D
96354
I
The Tessier-Lavigne/Hynes Irrevocable Trust 3
Common Stock
2021-12-29
4
S
0
10704
43.88
D
85650
I
The Tessier-Lavigne/Hynes Irrevocable Trust 3
Common Stock
2021-12-30
4
S
0
6002
45.31
D
79648
I
The Tessier-Lavigne/Hynes Irrevocable Trust 3
Common Stock
2021-12-30
4
S
0
800
45.72
D
78848
I
The Tessier-Lavigne/Hynes Irrevocable Trust 3
This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift.
Includes 2,074 restricted stock units.
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.42 to $45.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.42 to $45.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.51 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.66 to $45.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.18 to $44.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.67 to $45.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Tyler Nielsen, by power of attorney
2021-12-30